Thelial is dedicated to biological barriers.
Thelial is exclusively dedicated to improving treatment of diseases where biological barrier defects are a primary cause:
- Eosinophilic Esophagitis.
- Other epithelial inflammation diseases
- Neurodegenerative indications.
The mechanism of action we exploit is reinforcing biological barriers by targeting the cell polarity machinery. Thelial focuses on discovery and development of compounds to address mayor unmet market needs.
theLiTE™ (Thelial – Live Targeted Epithelia) is our proprietary targeted drug discovery platform technology; screening a library of more than 2000 drug candidates we have discovered more than twenty epithelium targeted candidates, validating theLiTE™. Three lead compounds are now being developed further. Please request a non-confidential presentation on out technology and portfolio.For more information contact us